4-Hexylresorcinol Ointment for Bone Remodeling Without Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic agents for bone diseases like osteoporosis often cause side effects such as osteoclast death, osteonecrosis, and discomfort due to injection, and there is a need for a safer, more convenient treatment that inhibits osteoclast activity while promoting osteoblast activity.
Innovation Solution
A pharmaceutical composition containing 4-hexylresorcinol (4-HR) is formulated as an ointment to inhibit osteoclast differentiation and activity while stimulating osteoblast differentiation, thereby improving bone density and strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If bisphosphonate-based drugs are used to suppress osteoclast activity, then bone resorption is inhibited, but side effects occur including osteoclast death, osteonecrosis of jaws, atypical fracture, and delayed fracture healing
Solution Approach 1:
The patent changes the chemical structure parameter from conventional bisphosphonate compounds to 4-hexylresorcinol, a natural phenolic compound. This structural parameter change fundamentally alters the mechanism of action to inhibit osteoclast activity without causing osteoclast death or osteonecrosis, thereby resolving the contradiction between effective bone resorption inhibition and avoidance of harmful side effects
Solution Approach 2:
The patent employs a natural, biodegradable compound (4-hexylresorcinol) instead of long-acting synthetic bisphosphonates. This natural compound provides transient osteoclast inhibition that does not accumulate to toxic levels, avoiding the harmful effects of persistent osteoclast suppression while maintaining therapeutic efficacy
2Productivity
If parathyroid hormone preparations are used to stimulate osteoblast activity, then bone formation is increased, but the treatment requires injection administration which causes discomfort
Solution Approach 1:
The patent replaces the mechanical injection administration system with a topical application system. 4-Hexylresorcinol can be administered as an ointment or cream that is applied to the skin, allowing the compound to be absorbed systemically and reach bone tissue without requiring needle injection, thus eliminating injection-related discomfort while maintaining osteoblast-stimulating effects
Solution Approach 2:
The patent uses the skin and bloodstream as intermediary pathways to deliver 4-hexylresorcinol to bone tissue. Instead of direct injection into bone or bloodstream, the compound is applied topically and transported through natural biological barriers (skin → blood → bone), providing a convenient non-invasive route that achieves the same therapeutic effect
3Strength
If estrogen preparations are used to reduce fractures, then bone strength is improved, but the treatment increases the risk of thrombosis and breast cancer
Solution Approach 1:
The patent extracts and utilizes the beneficial bone-protective effect of natural phenolic compounds (4-hexylresorcinol) while eliminating the harmful hormonal effects of estrogen. By focusing on a single non-hormonal compound that specifically targets bone metabolism, the invention separates the desired bone-strengthening effect from the unwanted thrombosis and cancer risks associated with estrogen therapy
Data Source
AI summary
The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models.